Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab
- 1 August 2005
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 6 (3) , 240-246
- https://doi.org/10.3816/cbc.2005.n.026
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II TrialJournal of Clinical Oncology, 2004
- Testing for HER-2/ neu in Breast Cancer: Is Fluorescence In Situ Hybridization Superior in Predicting Outcome?Advances in Anatomic Pathology, 2002
- Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer SpecimensJournal of Clinical Oncology, 2002
- neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.Journal of Clinical Oncology, 1998
- HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.Journal of Clinical Oncology, 1997
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.Proceedings of the National Academy of Sciences, 1992
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958